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Abstract
Background: Meningiomas are the most common primary tumors of the central nervous system. In patients
with WHO grade I meningiomas no adjuvant therapy is recommended after resection. In case of anaplastic
meningiomas (WHO grade III), adjuvant fractionated radiotherapy is generally recommended, regardless of the
extent of surgical resection. For atypical meningiomas (WHO grade II) optimal postoperative management has
not been clearly defined yet.
Methods: We conducted a retrospective analysis of patients treated for intracranial atypical meningioma at
Charité Universitätsmedizin Berlin from March 1999 to October 2018. Considering the individual circumstances
(risk of recurrence, anatomical location, etc.), patients were either advised to follow a wait-and-see approach
or to undergo adjuvant radiotherapy. Primary endpoint was progression-free survival (PFS).
Results: This analysis included 99 patients with atypical meningioma (WHO grade II). Nineteen patients received
adjuvant RT after primary tumor resection (intervention group). The remaining 80 patients did not receive any
further adjuvant therapy after surgical resection (control group). Median follow-up was 37 months. Median PFS
after primary resection was significantly longer in the intervention group than in the control group (64 m vs.
37 m, p = 0.009, HR = 0.204, 95% CI = 0.062–0.668). The influence of adjuvant RT was confirmed in multivariable
analysis (p = 0.041, HR = 0.192, 95% CI = 0.039–0.932).
Conclusions: Our study adds to the evidence that RT can improve PFS in patients with atypical meningioma.
Keywords: Atypical meningioma, Adjuvant radiotherapy, Fractionated stereotactic radiotherapy
Background
Meningiomas are the most common primary tumors of
the central nervous system, accounting for about one
third of all intracranial tumors. The median age of onset
is 65 years [1]. The vast majority of diagnosed meningi-
omas are benign, with only a small fraction being classi-
fied as malignant (grade II and III) [2]. The incidence of
meningioma increases with age across both sexes (10
per 100,000 women and 4.4 per 100,000 men) [1]. The
increased incidence in women suggests a relationship
between hormonal influences and the risk of developing
a meningioma. Postmenopausal women receiving hor-
mone replacement therapy have a significantly elevated
risk for meningiomas [3].
The histological origin of meningiomas is based on
clonal proliferation of arachnothelial cells of the menin-
ges [4]. Different genetic causes are accountable for the
development and progression of sporadic and familial
meningiomas [5]. Sporadic meningiomas are mainly asso-
ciated with focal chromosomal deletion and inactivation of
neurofibromatosis type 2 (NF2) tumor suppressor gene on
chromosome 22, which encodes a cytoskeletal-associated
protein with an inhibitory effect on the cell cycle [6]. Famil-
ial meningiomas are related to various mutations in the
NF2 gene [7, 8].
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The fourth edition of the WHO classification of tu-
mors of the central nervous system (2007) characterized
meningiomas into grades I, II, and III [9]. This classifica-
tion was primarily based on histopathological criteria:
Grade I (benign) was characterized by low proliferation
rates and a lack of anaplastic features; grade II (atypical)
by elevated mitotic rates and necrosis [9, 10]; grade III
(anaplastic) was defined by nuclear atypia and a highly
enhanced mitotic activity [10]. The fifth and most recent
edition of the WHO classification (2016) added the cri-
terion of infiltrating growth for the diagnosis of atypical
meningioma (WHO grade II) [11].
In patients with newly diagnosed meningioma, a wait-
and-see approach is considered when clinical conditions
allow it, with periodic clinical and radiographic follow-
up. However, regardless of the WHO grade, surgical re-
moval is still considered the treatment of choice [12].
Resection is indicated for large tumors, symptomatic pa-
tients, or fast growing tumors with mass effect [13]. The
extent of neurosurgical resection depends on tumor
localization, and is measured using the Simpson grade,
which is based on the surgeon’s intraoperative assess-
ment [14]. The operative intervention aims at complete
removal of all tumor parts, including associated dura
and underlying bone (Simpson grade I), while preserving
neurological function [13]. However, this may not always
be possible due to infiltration of venous sinuses, adher-
ence to blood vessels and cranial nerves or localization
at the base of the dura were dura cannot simply be
removed.
Modern radiation therapy (RT) is becoming increas-
ingly important in the treatment of meningiomas. RT
can be performed as stereotactic radiosurgery (SRS) or
as fractionated stereotactic RT (FSRT). Patients with
WHO grade I meningiomas, who are not undergoing
surgery, benefit from primary RT. In patients with in-
completely resected WHO grade I meningiomas, adju-
vant RT provides longer progression-free survival (PFS),
but a wait-and-see approach is preferred due to the slow
growth rate of the tumors [12, 15, 16]. In case of ana-
plastic meningiomas (WHO grade III), adjuvant fraction-
ated RT is generally recommended, regardless of the
extent of surgical resection [12]. This has been shown to
improve local tumor control and recurrence rates [17, 18].
For atypical meningiomas (WHO grade II), the primary
aim is to achieve a radical surgical tumor extirpation [12].
Despite elevated recurrence rates, optimal postopera-
tive management for atypical meningioma has not
been clearly defined yet. In particular, the role of ad-
juvant fractionated RT has remained controversial.
Depending on the extent of surgical resection, various
retrospective studies showed lower recurrence rates
and improved overall survival (OS) for adjuvant irra-
diated WHO grade II meningiomas [19–21]. However,
a large number of studies have found no definite
advantage of adjuvant RT, emphasizing the prognostic
significance of surgical resection and the risk of radi-
ation-induced toxicity [22–25]. Thus, retrospective
studies regarding adjuvant RT in atypical meningi-
omas have demonstrated inconsistent results, and the
results of ongoing randomized-controlled trials are
not yet available [26, 27].
The aims of this retrospective study were to investigate
the role of adjuvant RT in WHO grade II meningiomas
and to identify prognostic factors that have an impact on
PFS and OS.
Methods
Study population, data collection, and course of
treatment
We conducted a retrospective analysis of 99 patients
treated for intracranial atypical meningioma at Charité
Universitätsmedizin Berlin from March 1999 to October
2018. Patient identification was based on the review of
the hospital’s clinical cancer registry. Only adult patients
who underwent primary tumor resection were included.
The postoperative treatment decisions were made by an
interdisciplinary tumor board. Considering the individual
circumstances (risk of recurrence, anatomical location,
etc.), patients were either advised to follow a wait-and-see
approach or to undergo adjuvant RT. The regional ethics
committee approved this study (EA2/094/18).
Technical equipment and treatment planning
From 1995 to 2003, meningioma patients underwent
“sharp” fixation using a stereotactic head ring and an
oral bite plate. A 6-MV linear accelerator (LINAC) (Var-
ian Medical Systems, USA) with an add-on micro-multi-
leaf collimator (BrainLAB, Germany) was used.
Coordinates for SRS were set by a laser-based stereotac-
tic localizer, which allowed the delivery of shaped beams.
In 2004, the department started using Novalis Tx with
beam shaping capability using built-in multileaf collima-
tor (MLC) and image guidance with ExacTrac (Varian
Medical Systems, USA, and BrainLAB, Germany). The
image-guided frameless system enabled imaging with
high accuracy independent of couch position. A three-
dimensional treatment planning based on CT-co-regis-
tered with MRI was calculated using BrainScan (Brain-
LAB, Germany), which was later replaced by iPlan RT
(BrainLAB, Germany). The gross tumor volume (GTV)
was defined as the area of contrast enhancement on T1-
weighted MR images, and the planning target volume
(PTV) included a 1–2 mm isotropic safety margin. The
dose was prescribed to a reference point, representing
100%. Patients received 95% of the prescribed dose at
the PTV margin.
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Endpoints and variables
Follow-up was defined as the period between primary
tumor resection and last patient contact or death. PFS
was the primary endpoint of this study. OS was a sec-
ondary endpoint. Twelve intracranial tumor locations
were distinguished and divided into three groups de-
pending on their surgical risk according to the CLASS
algorithmic scale [28].
Statistics
Statistical analysis was performed using SPSS Statistics
(v. 25.0, IBM Inc., USA). Kaplan-Meier survival analysis
was used to calculate PFS after primary resection and
OS. The prognostic value of variables was evaluated
using univariable Cox-regression analysis. A multivari-
able Cox-regression analysis was performed to exclude
possible confounding factors. The frequency distribution
of continuous variables (patient age at first diagnosis and
pretherapeutic tumor volume) was examined for signifi-
cant differences with the unpaired Student’s t test. A
chi-square test was used to compare the distribution of
nominal variables (sex, intracranial tumor localization,
and type of salvage therapy). The distribution of ordinal
variables (Simpson resection grade) was compared using
the Mann-Whitney U test. For all statistical analyses,
data were considered statistically significant for p ≤ 0.05.
Results
Patient characteristics
This analysis included 99 patients with atypical meningi-
oma (WHO grade II). Nineteen patients received adju-
vant RT after primary tumor resection (intervention
group). The remaining 80 patients did not receive any
further adjuvant therapy after surgical resection (control
group). Patient characteristics are shown in Table 1. The
two groups were well balanced in terms of age, tumor
volume, sex, tumor location and Simpson grade. Median
follow-up until last contact or death was 37months.
Most patients in the intervention group received a single
dose of 1.8 Gy to a total dose of 54 or 59.4 Gy (median
total dose was 59.4 Gy).
Progression-free survival
Median PFS after primary resection was significantly
longer in the intervention group than in the control
group (64 m vs. 37 m, p = 0.009, HR = 0.204, 95% CI =
0.062–0.668, Fig. 1). The influence of adjuvant RT was
confirmed in multivariable analysis (p = 0.041, HR =
0.192, 95% CI = 0.039–0.932, Table 2). The factor “sex”
showed a significant impact on PFS in univariable ana-
lysis (p = 0.014, HR = 0.441 95% CI = 0.229–0.850). How-
ever, this was not confirmed in multivariable analysis.
Simpson resection status was identified as a factor influ-
encing PFS in univariable analysis (p = 0.009, HR = 1.488,
95% CI = 1.106–2.001). In multivariable analysis, a sig-
nificant role of Simpson resection status was confirmed
(p = 0.032, HR = 1.655, 95% CI = 1.043–2.626). Patient
age, tumor volume, and tumor location (skull base vs.
other, and high-risk location according to the CLASS al-
gorithmic scale vs. other) did not show a significant in-
fluence on PFS.
Overall survival
Univariable analysis of potential factors influencing OS
is shown in Table 3. Higher age (>median) was identified
as a significant predictor of OS in univariable analysis.
However, this was not confirmed in multivariable
analysis.
Discussion
In this retrospective study, we investigated the influence
of adjuvant RT on PFS in atypical meningioma patients.
In the multivariable analysis, patients who received adju-
vant RT demonstrated significantly longer PFS rates
compared with patients who did not receive adjuvant
RT. The second significant factor in multivariable ana-
lysis of PFS was Simpson grade of resection.
In the present study, male patients showed worse PFS
rates in univariable analysis. However, the factor gender
was eliminated in our multivariable model for PFS. This
is in accordance with most studies, which have not
found a significant association between gender and PFS
in grade II meningioma [29–32]. Nonetheless, two pub-
lished studies have shown an association between fe-
males and tumor relapse in univariable analysis [33, 34].
The median age in our patient cohort was 59 years,
which is comparable with the median age reported in
other studies [19, 32, 35]. We did not find an association
between age and PFS in uni- and multivariable analyses.
Higher age was a significant predictor of worse OS in
univariable analysis. Our finding, that age is not a pre-
dictor of PFS, is in accordance with most published data.
However, some studies have linked younger patient age
to improved PFS or OS. Champeaux and colleagues
(2016) showed that patients younger than 57 years at
surgery had a significantly higher PFS rate [36]; Endo
and colleagues (2016) demonstrated that age > 60 years
correlated with low PFS and OS [29].
In this study adjuvant RT significantly improved PFS
rates in uni- and multivariable analyses. However, the
PFS benefit did not translate into an OS benefit. The fact
that the benefit of adjuvant RT for PFS did not translate
into an OS benefit might be explained by the high rate
of salvage RT: Of 38 patients who showed recurrence in
the control group 35 received salvage RT at some point.
The PFS benefit is in accordance with numerous other
studies [19, 21, 32], and only one study showed reduced
PFS rates in patients who received adjuvant RT [37].
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A positive correlation between PFS and Simpson grade
I-III vs. Simpson grade IV-V was shown in univariable
and multivariable analyses, that did not translate into an
OS benefit. Most studies have shown a positive
correlation between the extent of surgical resection and
PFS in grade II meningioma [21, 22, 24, 30, 35]. How-
ever, it should be mentioned that some studies were not
able to confirm the described correlation [32, 37].








Median (Min/Max) Median (Min/Max) Median (Min/Max)
Patient age at first diagnosis (years) 59 59 59 0.49
(22/84) (26/75) (22/84)
Pretherapeutic tumor volume (cm3) 29.7 47.1 26.1 0.16
(0.8/153.9) (12.6/90.2) (0.8/153.9)
n (%) n (%) n (%)
Sex
Male 42 (42.4) 8 (42.1) 34 (42.5) 0.98
Female 57 (57.6) 11 (57.9) 46 (57.5)
Tumor location
Convexity 36 (36.4) 7 (36.8) 29 (36.3) 0.91
Olfactory groove / Planum sphenoidale 4 (4.0) 0 (0.0) 4 (5)
Lateral sphenoid wing / Temporal bone 6 (6.1) 2 (10.5) 4 (5)
Parasagittal / Falx 23 (23.2) 4 (21.1) 19 (23.8)
Cerebellopontine angle 3 (3.0) 1 (5.3) 2 (2.5)
Petroclival 1 (1.0) 0 (0) 1 (1.3)
Medial sphenoid wing / Clinoid / Orbital 17 (17.2) 4 (21.1) 13 (16.3)
Tuberculum sellae 3 (3.0) 0 (0) 3 (3.8)
Cavernous sinus 0 (0.0) 0 (0) 0 (0)
Tentorial 6 (6.1) 1 (5.3) 5 (6.3)
Foramen magnum 0 (0.0) 0 (0) 0 (0)
Optic nerve sheath 0 (0.0) 0 (0) 0 (0)
Simpson grade
1 24 (24.2) 5 (26.3) 19 (23.8) 0.39
2 35 (35.4) 4 (21.1) 31 (38.8)
3 1 (1.0) 0 (0) 1 (1.3)
4 11 (11.1) 4 (21.1) 7 (8.8)
5 1 (1.0) 1 (5) 0 (0)
Not documented 27 (27.3) 5 (26.3) 22 (27.5)
Salvage therapies
No recurrence 58 (58.6) 16 (84.2) 42 (52.5)
Resection 3 (3.0) 0 (0.0) 3 (3.8)
Radiotherapy 19 (19.2) 2 (10.5) 17 (21.3)
Resection and Radiotherapy 19 (19.2) 1 (5.3) 18 (22.5)
Fractionation scheme
Not irradiated 80 (80.8) 0 (0) 80 (100)
Normofractionation (1.8–2.2 Gy) 17 (17.1) 17 (89.5) 0 (0)
Hypofractionation (> 2.2–5 Gy) 1 (1) 1 (5.3) 0 (0)
SRS (> 5 Gy) 1 (1) 1 (5.3) 0 (0)
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We did not find any significant influence of tumor
location on PFS or OS when looking at the CLASS algo-
rithmic scale (low risk vs. moderate and high risk), and
when looking at skull base tumors vs. other locations.
Nonetheless, some studies have found a higher risk of
recurrence in “deep locations”, like the skull base and
the cerebral ventricles [32]. These results might have
been confounded, by the fact that “deep locations” are
more difficult to resect, causing a higher rate of subtotal
resections. Contrary to the mentioned study, Vranic and
colleagues showed reduced PFS rates in patients with tu-
mors in the parasagittal/falcine region [38].
We did not find any correlation between tumor volume
and PFS or OS. Other studies have shown low recurrence-
free survival rates for large diameter tumors [34].
The present study has some limitations. Firstly, the
retrospective approach is prone to bias. Secondly, it
should be pointed out that median follow-up to last
contact or death was only 37 months. Patient numbers
are relatively small in the intervention group. Add-
itionally, a high rate of not-documented Simpson
grades may interfere with interpretation of the results
of this study. Other factors than Simpson grade may
better predict tumor control rate, e.g. TERT mutation
status in the tumor, which was not assessed in this
study.
Conclusions
Grade II meningiomas show a high tendency of
tumor recurrence. Standard treatment of grade II
meningiomas is surgical resection, with the role of
adjuvant RT being unclear. In the present study,
Simpson grade I-III resection and adjuvant RT im-
proved PFS in multivariable analysis. Thus, our study
adds to the evidence that RT can improve PFS in pa-
tients with atypical meningioma.
Fig. 1 Cumulative progression-free survival after primary resection for intervention group (n = 19) and control group (n = 80) respectively (p =
0.009, HR = 0.204, 95% CI = 0.062–0.668)
Table 2 Uni- and multivariable analyses of progression-free survival. P-values ≤0.05 were defined as statistically significant (*). Tumor
localization in multivariable analysis was performed according to the CLASS algorithm (and not as “skullbase vs non-skullbase”)
because this information is already included in the CLASS algorithm
Univariable Multivariable
p HR 95% CI p HR 95% CI
Adjuvant radiotherapy (Intervention vs. control) 0.009* 0.204 0.062–0.668 0.041* 0.192 0.039–0.932
Sex (Male vs. female) 0.014* 0.441 0.229–0.850 0.422 0.666 0.247–1.796
Simpson resection grade14 (Grade IV/V vs. Grade I/II/III) 0.009* 1.488 1.106–2.001 0.032* 1.655 1.043–2.626
Patient age at first diagnosis (> median vs. ≤ median) 0.465 1.278 0.662–2.468 0.750 1.175 0.436–3.163
Pretherapeutic tumor volume (> median vs. ≤ median) 0.908 0.96 0.478–1.928 0.773 1.181 0.380–3.669
Intracranial tumor localization (CLASS moderate/high risk vs. low risk) 0.301 1.184 0.860–1.630 0.614 1.163 0.647–2.093
Intracranial tumor localization (non-skull base vs. skull base) 0.5 0.998 0.991–1.004
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